Tofacitinib combined with local low-dose ixekizumab injection benefits those with peripheral psoriatic arthritis
Ruiyuan Xia1
Weixin Zhang2
Jing Hang2
Zhiqiang Yin1
1.Department of Dermatology,the First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China2.Department of Ultrasound,the First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China
摘要：Dear Editor,
Treating psoriatic arthritis (PsA) is always difficult.Systemic treatments can be administered either orally or through intramuscular and intra-articular injection,including conventional synthetics,biologics and targeted synthetic disease-modifying antirheumatic drugs[1]. The alternatives,topical external therapies,are not effective on joint lesions due to drug permeability issues. Drugs injected into the articular cavity are also unsuitable for small peripheral joint lesions,the most common manifestations of PsA. The limited treatment options for PsA present a challenge.
机标关键词：tofacitinibixekizumabinjectionwitharthritisbenefitscombinedlocal
分类号：R758.63(皮肤病学与性病学)
论文发表日期：2024-01-30
在线出版日期：2026-03-31（本平台首次上网日期，不代表文献的发表时间）
页数：4( 中插8,92-94 )